Furthermore, Kaplan–Meier analysis and Cox regression showed no significant difference in the progression-free survival between GBM patients with a methylated MGMT promoter and those without a methylated MGMT promoter (p = 0.112, table2, Fig. 1); the hazard radio was 0.72 (95% CI: 0.48–1.09). Here, MGMT is linked to glioblastoma.